Celebrex May Reduce Lung Cancer Threat in Ex-Smokers
Controversial arthritis drug cuts down on a crucial protein needed for tumor growth.
All smokers, both those who are abstinent and those still puffing away, harbor the same primal fear: A doctor identifies a “spot” on a lung after a routine chest X-ray. The doctor arranges an appointment with a pulmonologist, who orders a CT scan, reviews it, and announces… it’s just a benign nodule. Nothing to worry about. That’s the happy scenario. The grim truth is that only about 15% of diagnosed lung cancer patients survive longer than 5 years. Lung cancer is a stone cold killer, and 85% of cases are smokers or former smokers. On Wednesday, a research team at the University of New Mexico announced that Celebrex, the controversial Cox-2 inhibitor used for the treatment of arthritis, may inhibit the growth of cells known to be precursors of lung cancer. Test subjects who took celecoxib had a 34% reduction in a protein called KI-67, which is an antigen necessary for cell proliferation, and is used as a marker for monitoring cell growth. In the case of breast and prostate cancer, the fraction of KI-67-positive cells in a tumor has proven to be a useful tool for determining how advanced a cancer is. The team found that the placebo group had a 3.8% increase over the same test period.
A lot more testing needs to be done. One potential problem: Celebrex increases the risk of cardiovascular disease and stroke, so future clinical studies will be limited to smokers with no other cardiovascular risk factors.